# Twist Bioscience Corp: Form 10-K/A for the period ended Sep 30, 2022

- Company: [Twist Bioscience Corp](/companies/twst.md) (CIK 1581280)
- Form: 10-K/A
- Filed: 2023-06-05
- Accepted by EDGAR: Jun 5, 2023, 16:31 ET
- Period: 2022-09-30
- Accession: 0001628280-23-020881
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1581280/000162828023020881/twst-20220930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1581280/000162828023020881/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2021-10-01 to 2022-09-30 | $203.6m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 12 months, 2021-10-01 to 2022-09-30 | $119.3m | us-gaap:CostOfRevenue |
| Research and development | 12 months, 2021-10-01 to 2022-09-30 | $120.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months, 2021-10-01 to 2022-09-30 | $212.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months, 2021-10-01 to 2022-09-30 | −$234.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2021-10-01 to 2022-09-30 | $80.0k | us-gaap:InterestExpense |
| Income tax | 12 months, 2021-10-01 to 2022-09-30 | −$10.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2021-10-01 to 2022-09-30 | −$217.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2021-10-01 to 2022-09-30 | −$4.04 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2021-10-01 to 2022-09-30 | −$4.04 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2021-10-01 to 2022-09-30 | 53,885,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2021-10-01 to 2022-09-30 | −$124.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2021-10-01 to 2022-09-30 | $101.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-09-30 | $378.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-09-30 | $596.5m | us-gaap:AssetsCurrent |
| Total assets | at 2022-09-30 | $961.4m | us-gaap:Assets |
| Current liabilities | at 2022-09-30 | $90.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-09-30 | $172.0m | us-gaap:Liabilities |
| Current portion of debt | at 2022-09-30 | $0 | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2022-09-30 | $789.4m | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1581280/000162828023020881/twst-20220930.htm

Filed Jun 5, 2023.
Source: SEC EDGAR, the filing index for accession 0001628280-23-020881. Last ingested by Listed: Nov 5, 2026, 16:39 ET. No prices; not investment advice.